Clinical trialNCT06026319RecruitingPhase 1Interventional

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

SponsorMarcela V. Maus, M.D.,Ph.D.Enrollment24Diffuse Large B Cell LymphomaFollicular LymphomaGrade 3b Follicular LymphomaHigh-grade B-cell LymphomaMantle Cell LymphomaMarginal Zone Lymphoma+4 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Matthew Frigault, MD
Massachusetts General Hospital
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Massachusetts General Hospital
Boston, Massachusetts, United States
Matthew Frigault, MD →
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CD79b-19 CAR T cellsCyclophosphamideFludarabine

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Oct 2023
Primary completion: 1 Jan 2027
Completion: 1 Jan 2028
Last update posted: 16 Mar 2026
Registered enrollment: 24
Registry id: NCT06026319

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.